436 related articles for article (PubMed ID: 28128578)
1. [Diabetes and dyslipidemia: Why are they so closely related?].
Rašlová K
Vnitr Lek; 2016; 62(11):908-911. PubMed ID: 28128578
[TBL] [Abstract][Full Text] [Related]
2. Management of dyslipidemias in patients with diabetes and chronic kidney disease.
Molitch ME
Clin J Am Soc Nephrol; 2006 Sep; 1(5):1090-9. PubMed ID: 17699330
[TBL] [Abstract][Full Text] [Related]
3. Type 2 diabetes, dyslipidemia, and vascular risk: rationale and evidence for correcting the lipid imbalance.
Carmena R
Am Heart J; 2005 Nov; 150(5):859-70. PubMed ID: 16290951
[TBL] [Abstract][Full Text] [Related]
4. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
[TBL] [Abstract][Full Text] [Related]
5. Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?
Agouridis AP; Rizos CV; Elisaf MS; Filippatos TD
Rev Diabet Stud; 2013; 10(2-3):171-90. PubMed ID: 24380091
[TBL] [Abstract][Full Text] [Related]
6. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
7. The Atherogenic Dyslipidemia Complex and Novel Approaches to Cardiovascular Disease Prevention in Diabetes.
Stahel P; Xiao C; Hegele RA; Lewis GF
Can J Cardiol; 2018 May; 34(5):595-604. PubMed ID: 29459241
[TBL] [Abstract][Full Text] [Related]
8. Diabetic dyslipidemia: from evolving pathophysiological insight to emerging therapeutic targets.
Ng DS
Can J Diabetes; 2013 Oct; 37(5):319-26. PubMed ID: 24500559
[TBL] [Abstract][Full Text] [Related]
9. Effects of High Intensity Statin Therapy in the Treatment of Diabetic Dyslipidemia in Patients with Coronary Artery Disease.
Vavlukis M; Kedev S
Curr Pharm Des; 2018; 24(4):427-441. PubMed ID: 29283060
[TBL] [Abstract][Full Text] [Related]
10. Management of Dyslipidemia in Patients with Hypertension, Diabetes, and Metabolic Syndrome.
Srikanth S; Deedwania P
Curr Hypertens Rep; 2016 Oct; 18(10):76. PubMed ID: 27730495
[TBL] [Abstract][Full Text] [Related]
11. Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins.
Tenenbaum A; Fisman EZ; Motro M; Adler Y
Cardiovasc Diabetol; 2006 Sep; 5():20. PubMed ID: 17002798
[TBL] [Abstract][Full Text] [Related]
12. [Diabetic dyslipidaemia and the atherosclerosis].
Márk L; Dani G
Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
[TBL] [Abstract][Full Text] [Related]
13. Treating dyslipidemia in patients with type 2 diabetes mellitus.
Frank ML; Gerhardt AM
Nurse Pract; 2015 Aug; 40(8):18-22; quiz 22-3. PubMed ID: 26164858
[TBL] [Abstract][Full Text] [Related]
14. Treating Dyslipidemias in the Primary Prevention of Atherosclerotic Cardiovascular Disease in Older Adults with Diabetes Mellitus.
Tan M; MacEachern MP
Clin Geriatr Med; 2020 Aug; 36(3):457-476. PubMed ID: 32586475
[TBL] [Abstract][Full Text] [Related]
15. REVIEW: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia.
Ginsberg HN
J Clin Endocrinol Metab; 2006 Feb; 91(2):383-92. PubMed ID: 16291700
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins.
Anabtawi A; Moriarty PM; Miles JM
Curr Cardiol Rep; 2017 Jul; 19(7):62. PubMed ID: 28528456
[TBL] [Abstract][Full Text] [Related]
17. The role of fenofibrate in clinical practice.
Zambon A; Cusi K
Diab Vasc Dis Res; 2007 Sep; 4 Suppl 3():S15-20. PubMed ID: 17935056
[TBL] [Abstract][Full Text] [Related]
18. [Consensus document on the treatment of dyslipidemia in diabetes].
Hormigo-Pozo A; Mancera-Romero J; Perez-Unanua MP; Alonso-Fernandez M; Lopez-Simarro F; Mediavilla-Bravo JJ;
Semergen; 2015 Mar; 41(2):89-98. PubMed ID: 25533449
[TBL] [Abstract][Full Text] [Related]
19. Attenuating cardiovascular risk factors in patients with type 2 diabetes.
Garber AJ
Am Fam Physician; 2000 Dec; 62(12):2633-42, 2645-6. PubMed ID: 11142470
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol.
Xiao C; Dash S; Morgantini C; Hegele RA; Lewis GF
Diabetes; 2016 Jul; 65(7):1767-78. PubMed ID: 27329952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
